Health
05 May 2021, 2:09 pm. 1 minute
Reuters exclusively reported that Eli Lilly & Co employees have accused a factory executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the U.S. plant producing the drugmaker’s COVID-19 treatment. An internal complaint asserts that an official at the company rewrote findings by technical experts to make the conclusions appear more favorable to the company.
Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: North America
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story